Don't Worry, Be Happy: Endocannabinoids and Cannabis at the Intersection of Stress and Reward

Annual Review of Pharmacology and Toxicology

Volumn 57, Issue , 2017, Pages 285-308

  Volkow, Nora D ^a   Hampson, Aidan J ^a   Baler, Ruben D ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

cannabis; endocannabinoids; marijuana; reward; stress; THC

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 3 [1 [CYCLOHEXYL(METHYL)CARBAMOYL] 1H IMIDAZOL 4 YL]PYRIDINE 1 OXIDE; ANANDAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABIS; DOPAMINE; ENDOCANNABINOID; N (3 PYRIDAZINYL) 4 [3 (5 TRIFLUOROMETHYL 2 PYRIDINYLOXY)BENZYLIDENE] 1 PIPERIDINECARBOXAMIDE; N (4 CHLORO 3 PYRIDINYL) 4 [(2,2 DIFLUORO 1,3 BENZODIOXOL 5 YL)METHYL] 1 PIPERAZINECARBOXAMIDE; NEUROTRANSMITTER; OXYTOCIN; PREGNENOLONE; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; ZCZ 011; MEDICAL CANNABIS;

ANALGESIA; ANXIETY DISORDER; CANNABIS ADDICTION; CLINICAL TRIAL (TOPIC); COGNITION; DEGRADATION; DEPRESSION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM DEPRESSION; MEMORY; MENTAL DISEASE; NEUROTOXICITY; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOLOGICAL WELL-BEING; REGULATORY MECHANISM; REVIEW; REWARD; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR; STRESS; SYNTHESIS; AGONISTS; ANIMAL; BRAIN; DRUG EFFECTS; HAPPINESS; MENTAL STRESS; METABOLISM; PHYSIOLOGY; PSYCHOLOGY;

ANIMALS; BRAIN; CANNABIS; ENDOCANNABINOIDS; HAPPINESS; HUMANS; MEDICAL MARIJUANA; MENTAL DISORDERS; RECEPTOR, CANNABINOID, CB1; REWARD; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

EID: 85009069185     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010716-104615     Document Type: Review

References (173)

1. WHO (World Health Organ.). 2016. Management of Substance Abuse. Geneva: World Health Organ. http://www.who.int/substance-abuse/en/
2. Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, et al. 2010. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62:588-631
3. BurnsHD, Van Laere K, Sanabria-Bohorquez S,Hamill TG, Bormans G, et al. 2007. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. PNAS 104:9800-5
4. Allen Inst. Brain Sci. 2016. Allen Brain Atlas. Seattle, WA: Allen Inst. http://www.brain-map.org/
5. Ceccarini J, Kuepper R, Kemels D, van Os J, Henquet C, Van Laere K. 2015. [18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict. Biol. 20:357-67
6. Sañudo-Peña MC, Romero J, Seale GE, Fernandez-Ruiz JJ, Walker JM. 2000. Activational role of cannabinoids on movement. Eur. J. Pharmacol. 391:269-74
7. Bajaj V, Pathak P,Mehrotra S, Singh V, Govil S, Khanna A. 2011. Cannabis induced periodic catatonia: a case report. Int. J. Mental Health Addict. 9:162-64
8. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, et al. 1995. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:54-61
9. Rom S, Persidsky Y. 2013. Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J. NeuroImmune Pharmacol. 8:608-20
10. Li Y, Kim J. 2015. Deletion of CB2 cannabinoid receptors reduces synaptic transmission and long-term potentiation in the mouse hippocampus. Hippocampus 26:275-81
11. Garcá-Gutiérrez MS, Ortega-Á lvaro A, Busquets-Garcá A, Pérez-Ortiz JM, Caltana L, et al. 2013. Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors. Neuropharmacology 73:388-96
12. Li Y, Kim J., 2016, CB2 cannabinoid receptor knockout in mice impairs contextual long-term memory and enhances spatial working memory. Neural Plast., 2016, 9817089
13. Turu G, Hunyady L. 2010. Signal transduction of the CB1 cannabinoid receptor. J. Mol. Endocrinol. 44:75-85
14. Rubino T, Vigan ò D, Premoli F, Castiglioni C, Bianchessi S, et al. 2006. Changes in the expression of G protein-coupled receptor kinases and-arrestins in mouse brain during cannabinoid tolerance: a role for RAS-ERK cascade. Mol. Neurobiol. 33:199-213
15. Dudok B, Barna L, Ledri M, Szabo SI, Szabadits E, et al. 2015. Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling. Nat. Neurosci. 18:75-86
16. Gyombolai P, Boros E, Hunyady L, Turu G. 2013. Differential-arrestin2 requirements for constitutive and agonist-induced internalization of the CB1 cannabinoid receptor. Mol. Cell. Endocrinol. 372:116-27
17. Khajehali E, Malone DT, Glass M, Sexton PM, Christopoulos A, Leach K. 2015. Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor. Mol. Pharmacol. 88:368-79
18. Laprairie RB, Bagher AM, Kelly ME, Dupré DJ, Denovan-Wright EM. 2014. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. J. Biol. Chem. 289:24845-62
19. Lerner TN, Kreitzer AC. 2012. RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits. Neuron 73:347-59
20. Alger BE, Kim J. 2011. Supply and demand for endocannabinoids. Trends Neurosci. 34:304-15
21. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, et al. 2004. Segregation of two endocannabinoid-hydrolyzing enzymes into pre-and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur. J. Neurosci. 20:441-58
22. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, et al. 2010. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat. Neurosci. 13:951-57
23. Ohno-Shosaku T, Tanimura A, Hashimotodani Y, Kano M. 2012. Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist 18:119-32
24. Okamoto Y, Tsuboi K, Ueda N. 2009. Enzymatic formation of anandamide. Vitam. Horm. 81:1-24
25. SimonGM, Cravatt BF. 2008. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J. Biol. Chem. 283:9341-49
26. Ohno-Shosaku T, KanoM. 2014. Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr. Opin. Neurobiol. 29:1-8
27. Ladarre D, Roland AB, Biedzinski S, Ricobaraza A, Lenkei Z. 2014. Polarized cellular patterns of endocannabinoid production and detection shape cannabinoid signaling in neurons. Front. Cell. Neurosci. 8:426
28. Lee SH, LedriM, Toth B,Marchionni I, Henstridge CM, et al. 2015. Multiple forms of endocannabinoid and endovanilloid signaling regulate the tonic control of GABA release. J. Neurosci. 35:10039-57
29. Egertová M, Cravatt BF, Elphick MR. 2003. Comparative analysis of fatty acid amide hydrolase and CB1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119:481-96
30. Cristino L, Starowicz K, De Petrocellis L, Morishita J, Ueda N, et al. 2008. Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience 151:955-68
31. Ross RA. 2003. Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol. 140:790-801
32. Shonesy BC, Winder DG, Patel S, Colbran RJ. 2015. The initiation of synaptic 2-AG mobilization requires both an increased supply of diacylglycerol precursor and increased postsynaptic calcium. Neuropharmacology 91:57-62
33. Maejima T, Oka S, Hashimotodani Y, Ohno-Shosaku T, Aiba A, et al. 2005. Synaptically driven endocannabinoid release requiresCa2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase C4 signaling cascade in the cerebellum. J. Neurosci. 25:6826-35
34. RamikieTS, Nyilas R, Bluett RJ,Gamble-George JC,Hartley ND, et al. 2014. Multiple mechanistically distinct modes of endocannabinoid mobilization at central amygdala glutamatergic synapses. Neuron 81:1111-25
35. Hashimotodani Y, Ohno-Shosaku T, TsubokawaH, Ogata H, Emoto K, et al. 2005. Phospholipase C serves as a coincidence detector through its Ca2+ dependency for triggering retrograde endocannabinoid signal. Neuron 45:257-68
36. Yamasaki M, Matsui M, Watanabe M. 2010. Preferential localization of muscarinic M1 receptor on dendritic shaft and spine of cortical pyramidal cells and its anatomical evidence for volume transmission. J. Neurosci. 30:4408-18
37. Ohno-Shosaku T, Shosaku J, Tsubokawa H, KanoM. 2002. Cooperative endocannabinoid production by neuronal depolarization and group I metabotropic glutamate receptor activation. Eur. J. Neurosci. 15:953-61
38. Kim J, Isokawa M, Ledent C, Alger BE. 2002. Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J. Neurosci. 22:10182-91
39. Uchigashima M, Yamazaki M, Yamasaki M, Tanimura A, Sakimura K, et al. 2011. Molecular and morphological configuration for 2-arachidonoylglycerol-mediated retrograde signaling at mossy cellgranule cell synapses in the dentate gyrus. J. Neurosci. 31:7700-14
40. Viader A, Blankman JL, Zhong P, Liu X, Schlosburg JE, et al. 2015. Metabolic interplay between astrocytes and neurons regulates endocannabinoid action. Cell Rep. 12:798-808
41. Pan B, Wang W, Long JZ, Sun D, Hillard CJ, et al. 2009. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate ( JZL184) enhances retrograde endocannabinoid signaling. J. Pharmacol. Exp. Ther. 331:591-97
42. Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, et al. 2005. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol. Pharmacol. 68:1196-202
43. Huang GZ, Woolley CS. 2012. Estradiol acutely suppresses inhibition in the hippocampus through a sex-specific endocannabinoid and mGluR-dependent mechanism. Neuron 74:801-8
44. GonsiorekW,LunnC, Fan X, Narula S, LundellD,HipkinRW.2000. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol. Pharmacol. 57:1045-50
45. Smaga I, Bystrowska B, Gawlinski D, Pomierny B, Stankowicz P, Filip M. 2014. Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures. Neurotoxicity Res. 26:190-206
46. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, et al. 2008. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat. Neurosci. 11:152-59
47. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, et al. 2003. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163:463-68
48. Jenniches I, Ternes S, Albayram O, Otte DM, Bach K, et al. 2015. Anxiety, stress, and fear response in mice with reduced endocannabinoid levels. Biol. Psychiatry 79:858-68
49. Gao Y, Vasilyev DV,Goncalves MB, Howell FV,Hobbs C, et al. 2010. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J. Neurosci. 30:2017-24
50. Khlaifia A, Farah H, Gackiere F, Tell F. 2013. Anandamide, cannabinoid type 1 receptor, and NMDA receptor activation mediate non-Hebbian presynaptically expressed long-term depression at the first central synapse for visceral afferent fibers. J. Neurosci. 33:12627-37
51. Straiker A, Hu SS, Long JZ, Arnold A, Wager-Miller J, et al. 2009. Monoacylglycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons. Mol. Pharmacol. 76:1220-27
52. Hohmann AG, Suplita RL II, Bolton NM, Neely MH, Fegley D, et al. 2005. An endocannabinoid mechanism for stress-induced analgesia. Nature 435:1108-12
53. Parsons LH, Hurd YL. 2015. Endocannabinoid signalling in reward and addiction.Nat. Rev. Neurosci. 16:579-94
54. Busquets-Garcia A, Desprez T,Metna-Laurent M, Bellocchio L, Marsicano G, Soria-Gomez E. 2015. Dissecting the cannabinergic control of behavior: The where matters. BioEssays 37:1215-25
55. Morena M, Patel S, Bains JS, Hill MN. 2016. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology 41:80-102
56. GreggLC, Jung KM, Spradley JM, Nyilas R, SuplitaRLII, et al. 2012. Activation of type 5metabotropic glutamate receptors and diacylglycerol lipase-alpha initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. J. Neurosci. 32:9457-68
57. McEwen BS. 2007. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev. 87:873-904
58. Viana TG, Hott SC, Resstel LB, Aguiar DC,Moreira FA. 2015. Anti-aversive role of the endocannabinoid system in the periaqueductal gray stimulation model of panic attacks in rats. Psychopharmacology 232:1545-53
59. Gunduz-Cinar O, MacPherson KP, Cinar R, Gamble-George J, Sugden K, et al. 2013. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol. Psychiatry 18:813-23
60. Woodhams SG, Sagar DR, Burston JJ, Chapman V. 2015. The role of the endocannabinoid system in pain. Handb. Exp. Pharmacol. 227:119-43
61. AgarwalN, Pacher P, Tegeder I, Amaya F, Constantin CE, et al. 2007. Cannabinoidsmediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 10:870-79
62. Booker L, Kinsey SG, Abdullah RA, Blankman JL, Long JZ, et al. 2012. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br. J. Pharmacol. 165:2485-96
63. Romero TR, Resende LC, Guzzo LS, Duarte ID. 2013. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. Anesth. Analg. 116:463-72
64. Lim J, Igarashi M, Jung KM, Butini S, Campiani G, Piomelli D. 2015. Endocannabinoid modulation of predator stress-induced long-term anxiety in rats. Neuropsychopharmacology 41:1329-39
65. Rácz I, Nent E, Erxlebe E, Zimmer A. 2015. CB1 receptors modulate affective behaviour induced by neuropathic pain. Brain Res. Bull. 114:42-48
66. Fuss J, Steinle J, Bindila L, Auer MK, Kirchherr H, et al. 2015. A runner's high depends on cannabinoid receptors in mice. PNAS 112:13105-8
67. Koltyn KF, Brellenthin AG, Cook DB, Sehgal N, Hillard C. 2014. Mechanisms of exercise-induced hypoalgesia. J. Pain 15:1294-304
68. Heyman E, Gamelin FX, Goekint M, Piscitelli F, Roelands B, et al. 2012. Intense exercise increases circulating endocannabinoid and BDNF levels in humans-possible implications for reward and depression. Psychoneuroendocrinology 37:844-51
69. Morgan CJA, Page E, Schaefer C, Chatten K,Manocha A, et al. 2013. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br. J. Psychiatry 202:381-82
70. Häring M, Enk V, Aparisi Rey A, Loch S, Ruiz de Azua I, et al. 2015. Cannabinoid type-1 receptor signaling in central serotonergic neurons regulates anxiety-like behavior and sociability. Front. Behav. Neurosci. 9:235
71. Hill MN, McLaughlin RJ, Pan B, Fitzgerald ML, Roberts CJ, et al. 2011. Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J. Neurosci. 31:10506-15
72. Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, et al. 2013. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol. Psychiatry 18:1034-40
73. Pietrzak RH, Huang Y, Corsi-Travali S, Zheng MQ, Lin SF, et al. 2014. Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors. Neuropsychopharmacology 39:2519-28
74. Mayer TA,MatarMA,Kaplan Z, Zohar J,Cohen H. 2014. Blunting of theHPA-axis underlies the lack of preventive efficacy of early post-stressor single-dose Delta-9-tetrahydrocannabinol (THC). Pharmacol. Biochem. Behav. 122:307-18
75. Solinas M, Goldberg SR, Piomelli D. 2008. The endocannabinoid system in brain reward processes. Br. J. Pharmacol. 154:369-83
76. Wang H, Lupica CR. 2014. Release of endogenous cannabinoids from ventral tegmental area dopamine neurons and themodulation of synaptic processes. Prog.Neuro-Psychopharmacol. Biol. Psychiatry 52:24-27
77. Oleson EB, Beckert MV, Morra JT, Lansink CS, Cachope R, et al. 2012. Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum. Neuron 73:360-73
78. Matyas F, Urban GM, Watanabe M, Mackie K, Zimmer A, et al. 2008. Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology 54:95-107
79. Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL. 2004. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J. Neurosci. 24:53-62
80. Alvarez-Jaimes L, Polis I, Parsons LH. 2008. Attenuation of cue-induced heroin-seeking behavior by cannabinoid CB1 antagonist infusions into the nucleus accumbens core and prefrontal cortex, but not basolateral amygdala. Neuropsychopharmacology 33:2483-93
81. Riegel AC, Lupica CR. 2004. Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J. Neurosci. 24:11070-78
82. Floresco SB, Blaha CD, Yang CR, Phillips AG. 2001. Modulation of hippocampal and amygdalarevoked activity of nucleus accumbens neurons by dopamine: cellular mechanisms of input selection. J. Neurosci. 21:2851-60
83. Ward SJ, Dykstra LA. 2005. The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav. Pharmacol. 16:381-88
84. Fattore L, Melis M, Fadda P, Pistis M, Fratta W. 2010. The endocannabinoid system and nondrug rewarding behaviours. Exp. Neurol. 224:23-36
85. WeiD, Lee D, CoxCD, Karsten CA, Peñagarikano O, et al. 2015. Endocannabinoid signalingmediates oxytocin-driven social reward. PNAS 112:14084-89
86. Schechter M, Weller A, Pittel Z, Gross M, Zimmer A, Pinhasov A. 2013. Endocannabinoid receptor deficiency affects maternal care and alters the dam's hippocampal oxytocin receptor and brain-derived neurotrophic factor expression. J. Neuroendocrinol. 25:898-909
87. Russo R, D'Agostino G,Mattace Raso G, Avagliano C, Cristiano C, et al. 2012. Central administration of oxytocin reduces hyperalgesia in mice: implication for cannabinoid and opioid systems. Peptides 38:81-88
88. Koob GF, Volkow ND. 2010. Neurocircuitry of addiction. Neuropsychopharmacology 35:217-38
89. Sidhpura N, Parsons LH. 2011. Endocannabinoid-mediated synaptic plasticity and addiction-related behavior. Neuropharmacology 61:1070-87
90. Massi L, Elezgarai I, Puente N, Reguero L, Grandes P, et al. 2008. Cannabinoid receptors in the bed nucleus of the stria terminalis control cortical excitation of midbrain dopamine cells in vivo. J. Neurosci. 28:10496-508
91. Reisiger AR, Kaufling J, Manzoni O, Cador M, Georges F, Caillé S. 2014. Nicotine self-administration induces CB1-dependent LTP in the bed nucleus of the stria terminalis. J. Neurosci. 34:4285-92
92. Terzian AL, Drago F, Wotjak CT, Micale V. 2011. The dopamine and cannabinoid interaction in the modulation of emotions and cognition: assessing the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors. Front. Behav. Neurosci. 5:49
93. Blume LC, Bass CE, Childers SR, Dalton GD, RobertsDCS, et al. 2013. Striatal CB1 andD2 receptors regulate expression of each other, CRIP1A and delta opioid systems. J. Neurochem. 124(6):808-20
94. Bergamaschi MM, Queiroz RH, Chagas MH, deOliveira DC,DeMartinis BS, et al. 2011. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-näve social phobia patients. Neuropsychopharmacology 36(6):1219-26
95. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, et al. 2016. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 15(3):270-78
96. Volkow ND, Baler RD, Compton WM, Weiss SR. 2014. Adverse health effects of marijuana use. N. Engl. J. Med. 370:2219-27
97. van der Pol P, Liebregts N, Brunt T, van Amsterdam J, de Graaf R, et al. 2014. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction 109:1101-9
98. Maccarrone M, Guzman M, Mackie K, Doherty P, Harkany T. 2014. Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. Nat. Rev. Neurosci. 15:786-801
99. GlassM, DragunowM, Faull RL. 1997. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77:299-318
100. Romero J, Garcia-Palomero E, Berrendero F, Garcia-Gil L, Hernandez ML, et al. 1997. Atypical location of cannabinoid receptors in white matter areas during rat brain development. Synapse 26:317-23
101. Kowalczyk T, Pontious A, Englund C,Daza RA, Bedogni F, et al. 2009. Intermediate neuronal progenitors (basal progenitors) produce pyramidal-projection neurons for all layers of cerebral cortex. Cereb. Cortex 19:2439-50
102. Mulder J, Aguado T, Keimpema E, Barabás K, Ballester Rosado CJ, et al. 2008. Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. PNAS 105:8760-65
103. Keimpema E, Barabás K, Morozov YM, Tortoriello G, Torii M, et al. 2010. Differential subcellular recruitment ofmonoacylglycerol lipase generates spatial specificity of 2-arachidonoyl glycerol signaling during axonal pathfinding. J. Neurosci. 30:13992-4007
104. Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, et al. 2007. Hardwiring the brain: Endocannabinoids shape neuronal connectivity. Science 316:1212-16
105. AguadoT,Monory K, Palazuelos J, Stella N, Cravatt B, et al. 2005. The endocannabinoid system drives neural progenitor proliferation. FASEB J. 19:1704-6
106. Saez TMM, Aronne MP, Caltana L, Brusco AH. 2014. Prenatal exposure to the CB1 and CB2 cannabinoid receptor agonistWIN55,212-2 altersmigration of early-born glutamatergic neurons and GABAergic interneurons in the rat cerebral cortex. J. Neurochem. 129:637-48
107. Kim D, Thayer SA. 2001. Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J. Neurosci. 21:RC146
108. Tortoriello G, Morris CV, Alpar A, Fuzik J, Shirran SL, et al. 2014. Miswiring the brain:-9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO J. 33:668-85
109. DiNieri JA, Hurd YL. 2012. Rat models of prenatal and adolescent cannabis exposure. Methods Mol. Biol. 829:231-42
110. DiNieri JA, Wang X, Szutorisz H, Spano SM, Kaur J, et al. 2011. Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. Biol. Psychiatry 70:763-69
111. Silva L, Harte-Hargrove L, Izenwasser S, Frank A, Wade D, Dow-Edwards D. 2015. Sexspecific alterations in hippocampal cannabinoid 1 receptor expression following adolescent delta-9-tetrahydrocannabinol treatment in the rat. Neurosci. Lett. 602:89-94
112. Keeley RJ, Trow J, McDonald RJ. 2015. Strain and sex differences in puberty onset and the effects of THC administration on weight gain and brain volumes. Neuroscience 305:328-42
113. Cooper ZD, HaneyM. 2016. Sex-dependent effects of cannabis-induced analgesia. Drug AlcoholDepend. 167:112-20
114. Fogel JS, Kelly TH, Westgate PM, Lile JA. 2016. Sex differences in the subjective effects of oral-9-THC in cannabis users. Pharmacol. Biochem. Behav. In press. https://doi.org/10.1016/j.pbb. 2016.01.007
115. Schneider M, Kasanetz F, Lynch DL, Friemel CM, Lassalle O, et al. 2015. Enhanced functional activity of the cannabinoid type-1 receptor mediates adolescent behavior. J. Neurosci. 35:13975-88
116. Hoffman AF, Lupica CR. 2013. Synaptic targets of-9-tetrahydrocannabinol in the central nervous system. Cold Spring Harb. Perspect. Med. 3:a012203
117. Boileau I, Mansouri E,Williams B, Le Foll B, Rusjan P, et al. 2016. Fatty acid amide hydrolase binding in brain of cannabis users: imaging with the novel radiotracer [11C]CURB. Biol. Psychiatry. 80:691-701
118. Iversen L. 2003. Cannabis and the brain. Brain 126:1252-70
119. Volkow ND, Gillespie H, MullaniN, Tancredi L, Grant C, et al. 1991. Cerebellar metabolic activation by delta-9-tetrahydro-cannabinol in human brain: a study with positron emission tomography and 18F-2-fluoro-2-deoxyglucose. Psychiatry Res. 40:69-78
120. Ramaekers JG, Berghaus G, van Laar M, Drummer OH. 2004. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend. 73:109-19
121. Batalla A, Bhattacharyya S, Yucel M, Fusar-Poli P, Crippa JA, et al. 2013. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLOS ONE 8:e55821
122. Yucel M, Solowij N, Respondek C, Whittle S, Fornito A, et al. 2008. Regional brain abnormalities associated with long-term heavy cannabis use. Arch. Gen. Psychiatry 65:694-701
123. Ashtari M, Avants B, Cyckowski L, Cervellione KL, Roofeh D, et al. 2011. Medial temporal structures and memory functions in adolescents with heavy cannabis use. J. Psychiatric Res. 45:1055-66
124. Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE. 2012. Grey matter alterations associated with cannabis use: results of a VBM study in heavy cannabis users and healthy controls. NeuroImage 59:3845-51
125. Matochik JA, Eldreth DA, Cadet JL, Bolla KI. 2005. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend. 77:23-30
126. Abel EL. 1971. Marihuana and memory: acquisition or retrieval Science 173:1038-40
127. Miller LL, Cornett TL, Brightwell DR,McFarland DJ, Drew WG,Wikler A. 1977. Marijuana: effects on storage and retrieval of prose material. Psychopharmacology 51:311-16
128. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, et al. 2016. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry 73:292-97
129. RanganathanM,D'SouzaDC. 2006. The acute effects of cannabinoids onmemory in humans: a review. Psychopharmacology 188:425-44
130. Anthony JC. 2006. The epidemiology of cannabis dependence. In Cannabis Dependence: Its Nature, Consequences and Treatment, ed. R Roffman, RS Stephens, pp. 58-105. Cambridge, UK: Cambridge Univ. Press
131. Anthony JC. 2012. Steppingstone and gateway ideas: a discussion of origins, research challenges, and promising lines of research for the future. Drug Alcohol Depend. 123(Suppl. 1):S99-104
132. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, et al. 2012. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol. Psychiatry 17:642-49
133. Ceccarini J, Hompes T, Verhaeghen A, Casteels C, Peuskens H, et al. 2014. Changes in cerebral CB1 receptor availability after acute and chronic alcohol abuse and monitored abstinence. J. Neurosci. 34:2822-31
134. Neumeister A, Normandin MD, Murrough JW, Henry S, Bailey CR, et al. 2012. Positron emission tomography shows elevated cannabinoidCB1 receptor binding inmen with alcohol dependence. Alcohol. Clin. Exp. Res. 36:2104-9
135. Gage SH, Hickman M, Zammit S. 2015. Association between cannabis and psychosis: epidemiologic evidence. Biol. Psychiatry 79:549-56
136. Sales-Carbonell C, Rueda-Orozco PE, Soria-G ómez E, Buzsáki G, Marsicano G, Robbe D. 2013. Striatal GABAergic and cortical glutamatergic neurons mediate contrasting effects of cannabinoids on cortical network synchrony. PNAS 110:719-24
137. den Boon FS, Werkman TR, Schaafsma-Zhao Q, Houthuijs K, Vitalis T, et al. 2015. Activation of type-1 cannabinoid receptor shifts the balance between excitation and inhibition towards excitation in layer II/III pyramidal neurons of the rat prelimbic cortex. Pflügers Archiv.: Eur. J. Physiol. 467:1551-64
138. Cortes-Briones J, Skosnik PD, Mathalon D, Cahill J, Pittman B, et al. 2015.-9-THC disrupts gamma ()-band neural oscillations in humans. Neuropsychopharmacology 40:2124-34
139. Morrison PD, Nottage J, Stone JM, Bhattacharyya S, Tunstall N, et al. 2011. Disruption of frontal theta coherence by-9-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology 36:827-36
140. TzilosGK, Cintron CB,Wood JBR, SimpsonNS, Young AD, et al. 2005. Lack of hippocampal volume change in long-term heavy cannabis users. Am. J. Addict. 14:64-72
141. Filbey F, Yezhuvath U. 2013. Functional connectivity in inhibitory control networks and severity of cannabis use disorder. Am. J. Drug Alcohol Abuse 39:382-91
142. Gruber SA, Rogowska J, Yurgelun-Todd DA. 2009. Altered affective response in marijuana smokers: an FMRI study. Drug Alcohol Depend. 105:139-53
143. Liberzon I, Phan KL. 2003. Brain-imaging studies of posttraumatic stress disorder. CNS Spectrums 8:641-50
144. Taylor SF, Kang J, Brege IS, Tso IF, Hosanagar A, Johnson TD. 2012. Meta-analysis of functional neuroimaging studies of emotion perception and experience in schizophrenia. Biol. Psychiatry 71:136-45
145. Bloomfield MAP, Morgan CJA, Egerton A, Kapur S, Curran HV, Howes OD. 2014. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol. Psychiatry 75:470-78
146. Bloomfield MAP, Morgan CJA, Kapur S, Curran HV, Howes OD. 2014. The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. Psychopharmacology 231:2251-59
147. van deGiessenE,Weinstein JJ, CassidyCM,Haney M, Dong Z, et al. 2016. Deficits in striatal dopamine release in cannabis dependence. Mol. Psychiatry. In press. https://doi.org/10.1038/mp.2016.21
148. Mizrahi R, Kenk M, Suridjan I, Boileau I, George TP, et al. 2014. Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology 39:1479-89
149. Kegeles LS, Abi-Dargham A, Frankle WG,Gil R, CooperTB, et al. 2010. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch. Gen. Psychiatry 67:231-39
150. Durstewitz D, Seamans JK. 2008. The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-O-methyltransferase genotypes and schizophrenia. Biol. Psychiatry 64:739-49
151. KelleyME, Wan CR, Broussard B, Crisafio A, Cristofaro S, et al. 2016. Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders. Schizophr. Res. 171(1-3):62-67
152. van der Meer FJ, Velthorst E, Genet. Risk Outcome Psychos. (GROUP) Investig. 2015. Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study. Psychol. Med. 45(9):1977-88
153. VolkDW,Eggan SM, Horti AG,WongDF,Lewis DA. 2014. Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia. Schizophr. Res. 159:124-29
154. UjikeH,MoritaY. 2004.Newperspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J. Pharmacol. Sci. 96:376-81
155. Ghosh A, Basu D. 2015. Cannabis and psychopathology: the meandering journey of the last decade. Indian J. Psychiatry 57:140-49
156. Monteleone P, Bifulco M, Maina G, Tortorella A, Gazzerro P, et al. 2010. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol. Res. 61:400-4
157. Andries A, Frystyk J, Flyvbjerg A, Stoving RK. 2014. Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. Int. J. Eating Disord. 47:18-23
158. Pacher P, Batkai S, Kunos G. 2006. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58:389-462
159. Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH. 2012. Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. Drug Testing Anal. 4:649-59
160. Webb CW,Webb SM. 2014. Therapeutic benefits of cannabis: a patient survey. Hawai'i J. Med. Public Health 73:109-11
161. Smaga I, Bystrowska B, Gawlinski D, Przegalinski E, Filip M. 2014. The endocannabinoid/endovanilloid system and depression. Curr. Neuropharmacol. 12:462-74
162. Suplita RL II, Eisenstein SA, Neely MH, Moise AM, Hohmann AG. 2008. Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stressinduced analgesia. Neuropharmacology 54:161-71
163. Beyer CE, Dwyer JM, Piesla MJ, Platt BJ, Shen R, et al. 2010. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol. Disease 39:148-55
164. Kedzior KK, Laeber LT. 2014. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population- A meta-analysis of 31 studies. BMC Psychiatry 14:136
165. Ghosh S, Kinsey SG, Liu QS, Hruba L, McMahon LR, et al. 2015. Full fatty acid amide hydrolase inhibition combined with partial monoacylglycerol lipase inhibition: augmented and sustained antinociceptive effects with reduced cannabimimetic side effects in mice. J. Pharmacol. Exp. Ther. 354:111-20
166. US Food Drug Admin. 2016. FDA finds drugs under investigation in the U.S. related to French BIA 10-2474 drug do not pose similar safety risks. News Release, Aug. 12. http://www.fda.gov/Drugs/DrugSafety/ucm482740.htm
167. Dohlman HG. 2015. Thematic Minireview Series: new directions in G protein-coupled receptor pharmacology. J. Biol. Chem. 290:19469-70
168. Ignatowska-Jankowska BM, Baillie GL, Kinsey S, Crowe M, Ghosh S, et al. 2015. A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects. Neuropsychopharmacology 40:2948-59
169. Valleé M, Vitiello S, Bellocchio L, Hébert-Chatelain E, Monlezun S, et al. 2014. Pregnenolone can protect the brain from cannabis intoxication. Science 343:94-98
170. Kenakin T, Christopoulos A. 2013. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12:205-16
171. ElSohlyMA, Mehmedic Z, Foster S, GonC,Chandra S, Church JC. 2016. Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in theUnited States. Biol. Psychiatry 79:613-19
172. Lee HJ, Groshek F, Petrovich GD, Cantalini JP, Gallagher M, Holland PC. 2005. Role of amygdalonigral circuitry in conditioning of a visual stimulus paired with food. J. Neurosci. 25:3881-88
173. Okate K, Nakamura Y. 2000. Possible pathways through which neurons of the shell of the nucleus accumbens influence the outflow of the core of the nucleus accumbens. Brain Dev. 22(Suppl. 1):S17-26